Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Common Equity for 10 consecutive years, with $139.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 540.02% to $139.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $139.1 million, a 540.02% increase, with the full-year FY2025 number at $139.1 million, up 540.02% from a year prior.
  • Common Equity was $139.1 million for Q4 2025 at Rhythm Pharmaceuticals, down from $148.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $380.9 million in Q1 2021 to a low of -$11.9 million in Q2 2025.
  • A 5-year average of $175.7 million and a median of $189.0 million in 2022 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 1226.95% in 2025; the steepest drop was 130.27% in 2025.
  • Rhythm Pharmaceuticals' Common Equity stood at $284.2 million in 2021, then decreased by 7.0% to $264.3 million in 2022, then plummeted by 35.76% to $169.8 million in 2023, then tumbled by 87.2% to $21.7 million in 2024, then surged by 540.02% to $139.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Common Equity are $139.1 million (Q4 2025), $148.8 million (Q3 2025), and -$11.9 million (Q2 2025).